器官移植中的细胞治疗。
Cellular therapies in organ transplantation.
机构信息
Nephrology and Transplantation, Department of Internal Medicine, Erasmus University Medical Center, Erasmus Medical Center, Rotterdam, The Netherlands.
Transplantation Research and Immunology Group, Nuffield Department of Surgical Sciences, John Radcliffe Hospital, University of Oxford, Oxford, UK.
出版信息
Transpl Int. 2021 Feb;34(2):233-244. doi: 10.1111/tri.13789. Epub 2021 Jan 15.
Abstract
Cellular therapy is a promising tool for improving the outcome of organ transplantation. Various cell types with different immunoregulatory and regenerative properties may find application for specific transplant rejection or injury-related indications. The current era is crucial for the development of cellular therapies. Preclinical models have demonstrated the feasibility of efficacious cell therapy in transplantation, early clinical trials have shown safety of several of these therapies, and the first steps towards efficacy studies in humans have been made. In this review, we address the current state of the art of cellular therapies in clinical transplantation and discuss monitoring tools and endpoints for these studies.
摘要
细胞疗法是改善器官移植结果的有前途的手段。具有不同免疫调节和再生特性的各种细胞类型可能适用于特定的移植排斥或损伤相关的适应证。当前是细胞疗法发展的关键时期。临床前模型证明了细胞疗法在移植中具有有效性，早期临床试验表明了其中几种疗法的安全性，并且已经迈出了在人体中进行疗效研究的第一步。在这篇综述中，我们讨论了细胞疗法在临床移植中的最新进展，并讨论了这些研究的监测工具和终点。
相似文献
1
Cellular therapies in organ transplantation.器官移植中的细胞治疗。
Transpl Int. 2021 Feb;34(2):233-244. doi: 10.1111/tri.13789. Epub 2021 Jan 15.
2
The impact of mesenchymal stem cell therapy in transplant rejection and tolerance.间充质干细胞治疗在移植排斥和耐受中的作用。
Curr Opin Organ Transplant. 2012 Aug;17(4):355-61. doi: 10.1097/MOT.0b013e328355a886.
3
Safety and Efficacy Endpoints for Mesenchymal Stromal Cell Therapy in Renal Transplant Recipients.间充质基质细胞治疗肾移植受者的安全性和疗效终点。
J Immunol Res. 2015;2015:391797. doi: 10.1155/2015/391797. Epub 2015 Jul 15.
4
Mesenchymal stromal cells for corneal transplantation: Literature review and suggestions for successful clinical trials.间质基质细胞用于角膜移植：文献综述及对成功临床试验的建议。
Ocul Surf. 2021 Apr;20:185-194. doi: 10.1016/j.jtos.2021.02.002. Epub 2021 Feb 16.
5
Mesenchymal Stromal Cells for Transplant Tolerance.间质基质细胞用于移植耐受。
Front Immunol. 2019 Jun 4;10:1287. doi: 10.3389/fimmu.2019.01287. eCollection 2019.
6
Mesenchymal stromal (stem) cells to improve solid organ transplant outcome: lessons from the initial clinical trials.间充质基质（干）细胞改善实体器官移植结局：初步临床试验的经验教训。
Curr Opin Organ Transplant. 2013 Dec;18(6):672-81. doi: 10.1097/MOT.0000000000000029.
7
Mesenchymal stromal cells in transplantation rejection and tolerance.间质基质细胞在移植排斥和耐受中的作用。
Cold Spring Harb Perspect Med. 2013 May 1;3(5):a015560. doi: 10.1101/cshperspect.a015560.
8
Mesenchymal Stromal Cells in Solid Organ Transplantation.实体器官移植中的间充质基质细胞。
Transplantation. 2020 May;104(5):923-936. doi: 10.1097/TP.0000000000003077.
9
A Large-Scale Bank of Organ Donor Bone Marrow and Matched Mesenchymal Stem Cells for Promoting Immunomodulation and Transplant Tolerance.大规模供者来源的骨髓和间充质干细胞库促进免疫调节和移植耐受。
Front Immunol. 2021 Feb 26;12:622604. doi: 10.3389/fimmu.2021.622604. eCollection 2021.
10
Cell Therapy in Solid-Organ Transplant.实体器官移植中的细胞疗法
Exp Clin Transplant. 2016 Nov;14(Suppl 3):6-13.
引用本文的文献
1
Regulatory Immune Cell-derived Exosomes: Modes of Action and Therapeutic Potential in Transplantation.调节性免疫细胞衍生的外泌体：移植中的作用模式及治疗潜力
Transplantation. 2025 Jul 1;109(7):1124-1137. doi: 10.1097/TP.0000000000005309. Epub 2025 Jan 27.
2
Allogeneic mesenchymal stromal cell therapy in kidney transplantation: should repeated human leukocyte antigen mismatches be avoided?肾移植中的同种异体间充质基质细胞疗法：是否应避免反复出现人类白细胞抗原错配？
Front Genet. 2024 Sep 27;15:1436194. doi: 10.3389/fgene.2024.1436194. eCollection 2024.
3
Research progress and prospects of benefit-risk assessment methods for umbilical cord mesenchymal stem cell transplantation in the clinical treatment of spinal cord injury.脐带间充质干细胞移植治疗脊髓损伤的获益-风险评估方法的研究进展与展望。
Stem Cell Res Ther. 2024 Jul 2;15(1):196. doi: 10.1186/s13287-024-03797-y.
4
Immuno-protective vesicle-crosslinked hydrogel for allogenic transplantation.免疫保护型囊泡交联水凝胶用于同种异体移植。
Nat Commun. 2024 Jun 18;15(1):5176. doi: 10.1038/s41467-024-49135-x.
5
Immune modulation in transplant medicine: a comprehensive review of cell therapy applications and future directions.移植医学中的免疫调节：细胞治疗应用及未来方向的全面综述
Front Immunol. 2024 Apr 8;15:1372862. doi: 10.3389/fimmu.2024.1372862. eCollection 2024.
6
Overcoming the challenges in translational development of natural killer cell therapeutics: An opinion paper.克服自然杀伤细胞疗法转化发展中的挑战：一篇观点论文。
Front Oncol. 2022 Dec 2;12:1062765. doi: 10.3389/fonc.2022.1062765. eCollection 2022.
7
Preconditioned Mesenchymal Stromal Cells to Improve Allotransplantation Outcome.预处理间充质基质细胞以改善同种异体移植的效果。
Cells. 2021 Sep 6;10(9):2325. doi: 10.3390/cells10092325.
8
Chimeric antigen receptor-modified human regulatory T cells that constitutively express IL-10 maintain their phenotype and are potently suppressive.嵌合抗原受体修饰的人调节性 T 细胞持续表达 IL-10 能保持其表型，并具有强大的抑制作用。
Eur J Immunol. 2021 Oct;51(10):2522-2530. doi: 10.1002/eji.202048934. Epub 2021 Aug 8.
本文引用的文献
1
Regulatory T cells for minimising immune suppression in kidney transplantation: phase I/IIa clinical trial.调节性 T 细胞减少肾移植中免疫抑制作用的研究：I/IIa 期临床试验。
BMJ. 2020 Oct 21;371:m3734. doi: 10.1136/bmj.m3734.
2
Identification, selection, and expansion of non-gene modified alloantigen-reactive Tregs for clinical therapeutic use.鉴定、选择和扩增非基因修饰的同种抗原反应性 Tregs 用于临床治疗用途。
Cell Immunol. 2020 Nov;357:104214. doi: 10.1016/j.cellimm.2020.104214. Epub 2020 Sep 9.
3
Functional effects of chimeric antigen receptor co-receptor signaling domains in human regulatory T cells.嵌合抗原受体共受体信号结构域在人调节性 T 细胞中的功能效应。
Sci Transl Med. 2020 Aug 19;12(557). doi: 10.1126/scitranslmed.aaz3866.
4
The Future of Regulatory T Cell Therapy: Promises and Challenges of Implementing CAR Technology.嵌合抗原受体 T 细胞疗法的未来：实施 CAR 技术的前景与挑战。
Front Immunol. 2020 Jul 24;11:1608. doi: 10.3389/fimmu.2020.01608. eCollection 2020.
5
The Fourth International Workshop on Clinical Transplant Tolerance.第四届临床移植耐受国际研讨会。
Am J Transplant. 2021 Jan;21(1):21-31. doi: 10.1111/ajt.16139. Epub 2020 Jul 22.
6
Regulatory cell therapy in kidney transplantation (The ONE Study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1/2A trials.肾移植中的调节性细胞治疗（ONE 研究）：七个非随机、单臂、1/2A 期的临床试验的协调设计和分析。
Lancet. 2020 May 23;395(10237):1627-1639. doi: 10.1016/S0140-6736(20)30167-7.
7
Banff 2019 Meeting Report: Molecular diagnostics in solid organ transplantation-Consensus for the Banff Human Organ Transplant (B-HOT) gene panel and open source multicenter validation.Banff 2019 会议报告：实体器官移植中的分子诊断- Banff 人类器官移植 (B-HOT) 基因面板共识和开源多中心验证。
Am J Transplant. 2020 Sep;20(9):2305-2317. doi: 10.1111/ajt.16059. Epub 2020 Jun 27.
8
Human leukocyte antigen selected allogeneic mesenchymal stromal cell therapy in renal transplantation: The Neptune study, a phase I single-center study.人类白细胞抗原选择同种异体间充质基质细胞治疗肾移植： Neptune 研究，一项 I 期单中心研究。
Am J Transplant. 2020 Oct;20(10):2905-2915. doi: 10.1111/ajt.15910. Epub 2020 May 6.
9
The emergence of regenerative medicine in organ transplantation: 1st European Cell Therapy and Organ Regeneration Section meeting.再生医学在器官移植中的出现：第 1 届欧洲细胞治疗和器官再生分会会议。
Transpl Int. 2020 Aug;33(8):833-840. doi: 10.1111/tri.13608. Epub 2020 Apr 28.
10
Potential Applications of Extracellular Vesicles in Solid Organ Transplantation.细胞外囊泡在实体器官移植中的潜在应用。
Cells. 2020 Feb 5;9(2):369. doi: 10.3390/cells9020369.
Zotero 插件